Table 2.

Univariate and multivariate analyses of the correlation of COPB2 with OS among HCC patients from TCGA cohort.

Clinical characteristics	HR	p value
Univariate analysis
Age (continuous)	1.250 (0.882−1.772)	0.210
Sex (male vs. female)	0.805 (0.564−1.147)	0.230
BMI (continuous)	0.974 (0.941−1.007)	0.124
T stage (T4/T3/T2/T1)	1.665 (1.390−1.993)	<0.0001∗∗∗∗
Lymph nodes (positive vs. negative)	1.948 (0.477−7.952)	0.353
Distant metastasis (positive vs. negative)	3.820 (1.201−12.146)	0.023∗
Stage (IV/III/II/I)	1.652 (1.349−2.024)	<0.0001∗∗∗∗
Grade (G4/G3/G2/G1)	1.127 (0.892−1.424)	0.317
Tumor status (with tumor vs. tumor-free)	1.604 (1.116−2.306)	0.011∗
Family cancer history (yes vs. no)	1.182 (0.819−1.707)	0.372
New tumor event (yes vs. no)	1.335 (0.932−1.913)	0.116
COPB2 expression (continuous)	1.068 (1.037−1.099)	<0.0001∗∗∗∗
Multivariate analysis
T stage (T4/T3/T2/T1)	2.074 (0.816−5.270)	0.125
Distant metastasis (positive vs. negative)	1.642 (0.282−9.544)	0.581
Stage (IV/III/II/I)	0.772 (0.269−2.215)	0.630
Tumor status (with tumor vs. tumor-free)	1.002 (0.487−2.064)	0.995
COPB2 expression (continuous)	2.011 (1.111−3.641)	0.021∗

HR: hazard ratio. ^∗p < 0.05 and ^∗∗∗∗p < 0.0001.